- POAI
addresses pressing need for a multi-omic approach in field of precision
medicine
- Global
precision medicine market is expected to reach total market value of
approximately $84 billion by 2026
- Predictive
Oncology’s ‘claim to fame’ is its inventory of over 150,000 tumors
covering over 137 types of cancer, with over 30,000 related to ovarian
cancer
In the burgeoning world of precision medicine, Predictive Oncology Inc. (NASDAQ: POAI) appears
ideally positioned to address one of the most pressing problems in the
industry: the need for a multi-omic approach to precision therapy that may
offer markedly improved patient outcomes over just genomics alone. POAI, a
leader in the cancer precision-medicine field, has a “major asset” in its
Helomics subsidiary, which specializes in ovarian cancer. Through its unique
patient derived (PDx) platform, which tests the drug response and biomarker
profile of the patient’s own tumor, and its vast database of historical tumor
profiles, Helomics provides clinical decision support tools today to assist
oncologists in individualizing cancer treatment.
Precision medicine is based on the idea of customizing
health care, making medical decisions and selecting treatments, practices and
prescriptions that are tailored to each individual patient rather than a
recommended general treatment approach. A recent Acumen Research and Reporting
article noted that the global precision medicine market is expected to reach
total market value of approximately $84 billion by 2026 with anticipated CAGR
growth of around 10% in terms of revenue between 2019 and 2026 (http://ibn.fm/vufVR).
That growth hasn’t gone unnoticed. Big pharma has invested
heavily in precision medicine, focusing its efforts on genomics and “big data”
to understand each patient’s genome in order to deliver targeted therapeutics.
“Success rates for these targeted therapies are low, and uptake in clinical
practice is patchy,” POAI reports on its website (http://ibn.fm/MywNK), noting a growing realization that
“just genomics is not enough to achieve the promise of personalized
therapeutics. A clear need has emerged for a multi-omic approach that may offer
a much greater chance of success. However, few comprehensive, multi-omic data
sets exist, and such data is difficult to access quickly as it is both costly
and time consuming to initiate prospective data collection — especially in
cancer.”
Multiomics, or the use of multiple omics technologies (i.e.,
genome, proteome, transcriptome, epigenome, microbiome, etc.) to study disease
in a more comprehensive manner has significant implications in the world of
health care – and Predictive Oncology owns powerful data and technology that
may make the company a clear frontrunner in the precision medicine space.
“Predictive’s major asset is its subsidiary Helomics, and
its claim to fame is its inventory of over 150,000 tumors covering over 137
types of cancer, with over 30,000 related to ovarian cancer, which is sort of
our specialty. In fact, this is the largest inventory of its kind in the
world,” POAI director and CEO Carl Schwartz stated in a news release (http://ibn.fm/e9EIC).
Furthermore, the data in POAI’s molecular information
platform are highly differentiated, the company explained, containing both
drug-response and biomarker data and with access to historical outcome data
from these individual patients. Predictive Oncology is working to gather
additional sequence data (mutation and gene expression) from these tumor
samples, coupling this with its unique drug response profiles to build
AI-driven predictive models of cancer that it believes will meet the unmet
market need for a multi-omic approach to the development of new drugs and
improve patient outcomes.
POAI is bringing precision medicine, or tailored
medical treatment using the individual characteristics of each patient, to the
treatment of cancer. Through the company’s Helomics division, the company
leverages its unique, clinically validated patient derived (PDx) smart tumor
profiling platform to provide oncologists with a road map to help individualize
therapy.
In addition, the company is leveraging artificial
intelligence and its proprietary database of over 150,000 cancer cases
tumors to build AI-driven models of tumor drug response to improve
outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
